Skip to main content

Table 1 Study participant characteristics at enrollment

From: MiR-1231 decrease the risk of cancer-related mortality in patients combined with non-small cell lung cancer and diabetes mellitus

Variation Total (n = 108) Cohort, median (IQR) P value
miR-1231 < 1.775 miR-1231 ≥ 1.775
Age (year) 64.08 ± 7.6 64.69 ± 7.76 63.48 ± 7.47 0.413
BMI (kg/m2) 23.9 ± 3.53 23.82 ± 3.75 23.98 ± 3.33 0.819
Serum CEA level (ng/mL) 3.9 (1.83, 13.43) 5.92 (2.41, 38.39) 3.12 (1.47, 6.91) 0.021*
Serum CRP level (μmol/L) 9.49 (2.38, 13.34) 11 (4.26, 13.28) 5.99 (2.14, 13.37) 0.227
Albumin level (g/L) 40.01 ± 5.21 39.46 ± 4.83 40.57 ± 5.56 0.272
Neutrophils count (109/L) 4.68 (3.53, 6.27) 4.72 (3.67, 6.08) 4.68 (3.37, 6.4) 0.549
Lymphocytes count (109/L) 1.68 (1.23, 2.15) 1.47 (1.18, 2.02) 1.75 (1.36, 2.3) 0.073
Hemoglobin level (g/L) 133 (123, 142.25) 133.5 (123.25, 144.75) 131.5 (123, 141.75) 0.412
Platelet count (109/L) 228.5 (186, 289) 225.5 (183.25, 291) 243.5 (200.25, 283.25) 0.365
PNI score 49.22 (44.03, 53.94) 47.62 (43.12, 51.64) 50.05 (44.48, 55.7) 0.101
NLR 2.9 (2.01, 4.49) 3.19 (2.37, 4.66) 2.69 (1.86, 3.87) 0.098
Gender (n %)     0.534
 Female 34 (31) 15 (28) 19 (35)  
 Male 74 (69) 39 (72) 35 (65)  
Pathologic type (n %)     0.547
 Adenocarcinoma 58 (54) 29 (54) 29 (54)  
 Mixed lung cancer 17 (16) 7 (13) 10 (19)  
 Large cell lung cancer 5 (5) 4 (7) 1 (2)  
 Squamous carcinoma 27 (25) 14 (26) 13 (24)  
 Others 1 (1) 0 (0) 1 (2)  
Metastasis, n (%)     0.177
 No 50 (46) 21 (39) 29 (54)  
 Yes 58 (54) 33 (61) 25 (46)  
Stage of NSCLC     0.005**
 Stage I 17 (16) 4 (7) 13 (24)  
 Stage II 8 (7) 6 (11) 2 (4)  
 Stage III 20 (19) 6 (11) 14 (26)  
 Stage IV 63 (58) 38 (70) 25 (46)  
Surgery (n %)     0.001**
 No 66 (61) 42 (78) 24 (44)  
 Yes 42 (39) 12 (22) 30 (56)  
Therapy of radiation (n %)     0.238
 No 65 (60) 29 (54) 36 (67)  
 Yes 43 (40) 25 (46) 18 (33)  
Application of platinum (n %)     1
 No 3 (3) 2 (4) 1 (2)  
 Yes 105 (97) 52 (96) 53 (98)  
Chemotherapy     0.573
 AP 45 (42) 25 (46) 20 (37)  
 DP 13 (12) 6 (11) 7 (13)  
 EP 14 (13) 8 (15) 6 (11)  
 GP 8 (7) 2 (4) 6 (11)  
 Others 28 (26) 13 (24) 15 (28)  
Target therapy (n %)     0.02*
 No 76 (70) 32 (59) 44 (81)  
 Yes 32 (30) 22 (41) 10 (19)  
Application of TKI (n %)     0.006**
 No 82 (76) 34 (63) 48 (89)  
 TKI I 19 (18) 15 (28) 4 (7) 0.006**
 TKI III 7 (6) 5 (9) 2 (4)  
Application of VEGF inhibitor, n (%)     0.775
 No 94 (87) 48 (89) 46 (85)  
 Yes 14 (13) 6 (11) 8 (15)  
KPS score, n (%)     0.013*
 20 1 (1) 0 (0) 1 (2)  
 50 3 (3) 2 (4) 1 (2)  
 60 1 (1) 1 (2) 0 (0)  
 70 9 (8) 6 (11) 3 (6)  
 80 31 (29) 22 (41) 9 (17)  
 90 40 (37) 16 (30) 24 (44)  
 100 23 (21) 7 (13) 16 (30)  
Smoking, n (%)     1
 No 51 (47) 26 (48) 25 (46)  
 Yes 57 (53) 28 (52) 29 (54)  
Hypertension, n (%)     1
 No 39 (36) 20 (37) 19 (35)  
 Yes 69 (64) 34 (63) 35 (65)  
Hyperlipemia, n (%)     0.215
 No 88 (81) 41 (76) 47 (87)  
 Yes 20 (19) 13 (24) 7 (13)  
Heart failure, n (%)     0.495
 No 106 (98) 52 (96) 54 (100)  
 Yes 2 (2) 2 (4) 0 (0)  
ACS, n (%)     1
 No 105 (97) 52 (96) 53 (98)  
 Yes 3 (3) 2 (4) 1 (2)  
  1. IQR, interquartile range; CRP, C-reactive protein; PNI, neutrophil lymphocyte ratio; NLR, neutrophil lymphocyte ratio; NSCLC, non-small-cell lung cancer; TKI, Tyrosine Kinase Inhibitor; VEGF, vascular endothelial growth factor; KPS, Karnofsky Performance Status; ACS, acute coronary syndrome. ***P < 0.001, **P < 0.01, *P < 0.05